Peripheral biomarkers of major depression and antidepressant treatment response: Current knowledge and future outlooks

In recent years, we have accomplished a deeper understanding about the pathophysiology of major depressive disorder (MDD). Nevertheless, this improved comprehension has not translated to improved treatment outcome, as identification of specific biologic markers of disease may still be crucial to fac...

Full description

Saved in:
Bibliographic Details
Published in:Journal of affective disorders 2018-06, Vol.233, p.3-14
Main Authors: Gadad, Bharathi S., Jha, Manish K., Czysz, Andrew, Furman, Jennifer L., Mayes, Taryn L., Emslie, Michael P., Trivedi, Madhukar H.
Format: Article
Language:English
Subjects:
Antidepressive Agents - therapeutic use
Biomarkers
Biomarkers - blood
Biosignatures
Depression
Depressive Disorder, Major - blood
Depressive Disorder, Major - drug therapy
Genomics
Humans
Metabolomics
Neuroimaging
Proteomics
Treatment Outcome
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:In recent years, we have accomplished a deeper understanding about the pathophysiology of major depressive disorder (MDD). Nevertheless, this improved comprehension has not translated to improved treatment outcome, as identification of specific biologic markers of disease may still be crucial to facilitate a more rapid, successful treatment. Ongoing research explores the importance of screening biomarkers using neuroimaging, neurophysiology, genomics, proteomics, and metabolomics measures. In the present review, we highlight the biomarkers that are differentially expressed in MDD and treatment response and place a particular emphasis on the most recent progress in advancing technology which will continue the search for blood-based biomarkers. Due to space constraints, we are unable to detail all biomarker platforms, such as neurophysiological and neuroimaging markers, although their contributions are certainly applicable to a biomarker review and valuable to the field. Although the search for reliable biomarkers of depression and/or treatment outcome is ongoing, the rapidly-expanding field of research along with promising new technologies may provide the foundation for identifying key factors which will ultimately help direct patients toward a quicker and more effective treatment for MDD. •We summarize current therapeutic interventions for depression and discuss the need for biomarker identification.•We discuss the utility of “omics” screening tools and their applicability to discovering biomarkers.•We review studies using blood based “omics” analyses with MDD and treatment response.
ISSN:0165-0327
1573-2517
DOI:10.1016/j.jad.2017.07.001